



Preora Diagnostics Chairman Vadim Backman Addresses Milken Institute Global Conference 2016

– Northwestern professor joins Nobel Laureate and other medical experts
for prestigious panel discussion –

EVANSTON, IL, May 4, 2016 – Preora Diagnostics Inc. Chairman Vadim Backman, PhD, provided an overview of the company’s PWS Nanocytology platform today at the Milken Institute Global Conference 2016. Dr. Backman joined Nobel Laureate Elizabeth Blackburn, president, Salk Institute and other experts during a plenary session lunch panel, “This Changes Everything: How Technology is Revolutionizing Medicine.”

Dr. Backman’s presentation focused on the need for dramatic improvements in the ability to detect cancer as early as possible, the benefits of a two-tiered approach to cancer screening and the promise of the company’s proprietary Partial Wave Spectroscopy (PWS) Nanocytology technology platform.

The Milken Institute audience heard the PWS Nanocytology platform be compared to one of the greatest medical breakthroughs in history: “In essence, this is the ‘nanotechnology Pap-smear’ for many, many cancers,” Dr. Backman said. “The Pap smear reduced cervical cancer mortality by more than 90%. Imagine if a nanotechnology Pap smear could do the same for other cancers. We could dramatically reduce cancer deaths.”

The four-day Global Conference convened some of the world's most extraordinary people to explore solutions to today's most pressing challenges in financial markets, industry sectors, health, government and education. In addition to Dr. Backman, other Global Conference speakers included Amgen Chairman and CEO Robert Bradway, National Cancer Institute Director L. Michelle Bennett, Memorial Sloan Kettering Cancer Center Director Peter Bach former British Prime Minister Tony Blair, California Governor Jerry Brown, former NATO Supreme Commander Wesley Clark, former Vice President Al Gore, and dozens of other experts from the worlds of science, entertainment, politics, arts, media, sports and technology.

To view Dr. Backman’s full remarks and selected excerpts, visit <http://www.PreoraDx.com/Presentations>.

About Preora Diagnostics

Preora Diagnostics Inc. is dedicated to helping people survive cancer through a proven, two-tiered approach to early detection. The company develops proprietary, low-cost, minimally invasive, highly sensitive and highly specific cancer screening tests using technology that detects and measures cellular changes at the nanoscale level. The screening tests are based on the proprietary Partial Wave Spectroscopy (PWS) Nanocytology platform, licensed exclusively by Preora through NanoCytomics, LLC and Northwestern University. For more information, visit www.PreoraDx.com.

###